Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886185 | 0.81 | RAB9A (0.36) | ALDH1A1KDM4ETSHRSMN1; SMN2RAB9A | |
| SCHEMBL17740013 | 0.80 | MAOB (0.38) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL21067103 | 0.80 | AGBL2 (0.40) | ALDH1A1TSHRCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL21527961 | 0.78 | TSHR (0.38) | KDM4ETSHRCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL20209550 | 0.78 | ALDH1A1 (0.38) | ALDH1A1KDM4ESMN1; SMN2RAB9ANPC1 | |
| SCHEMBL17057294 | 0.77 | SMN1; SMN2 (0.42) | ALDH1A1KDM4ETSHRCYP1A2CYP2D6 | |
| SCHEMBL2099046 | 0.76 | KDM4E (0.47) | ALDH1A1KDM4ETSHRCYP1A2CYP2D6 | |
| SCHEMBL4637326 | 0.76 | KDM4E (0.41) | ALDH1A1KDM4ESMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL26463315 | 0.75 | RIPK1 (0.34) | ALDH1A1RAB9ANPC1L3MBTL1 | |
| SCHEMBL22202148 | 0.74 | MEN1 (0.33) | KDM4ERAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4382519-A1 | CYCLIN K DEGRADATION AGENT | Adlai Nortye Biopharma Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-20230391778-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-12-07 | — | — | US | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| WO-2023049723-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | ORIC PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-11261195-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220033395-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210246133-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2021-08-12 | — | — | US | disclosed |
| US-20210214370-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2021-07-15 | — | — | US | disclosed |
| US-20170101409-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-04-13 | — | — | US | disclosed |
| WO-2015197567-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-30 | — | — | WO | disclosed |
| US-20150203509-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2015-07-23 | — | — | US | disclosed |
| EP-2385832-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2015-07-15 | — | — | EP | disclosed |
| US-8906909-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8461157-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. | 2013-04-25 | — | — | US | disclosed |
| EP-2557923-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | Curis, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2010080996-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101409-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN-2-ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | ALDH1A1 700/4885KDM4E 4502/4885TSHR 387/4885 |
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | ALDH1A1 3415/4885KDM4E 868/4885TSHR 2427/4885 |
| US-20210246133-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | ALDH1A1 700/4885KDM4E 4502/4885TSHR 387/4885 |
| US-11261195-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | ALDH1A1 3415/4885KDM4E 868/4885TSHR 2427/4885 |
| US-20210214370-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | ALDH1A1 3440/4885KDM4E 856/4885TSHR 2449/4885 |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | ALDH1A1 3440/4885KDM4E 856/4885TSHR 2449/4885 |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | ALDH1A1 3415/4885KDM4E 868/4885TSHR 2427/4885 |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | ALDH1A1 3415/4885KDM4E 868/4885TSHR 2427/4885 |
| US-20230391778-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | ALDH1A1 700/4885KDM4E 4502/4885TSHR 387/4885 |
| US-20150203509-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | ALDH1A1 3440/4885KDM4E 856/4885TSHR 2449/4885 |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | KRAS, HRAS, KSR2 | ALDH1A1 1626/4885KDM4E 1169/4885TSHR 3108/4885 |
| US-20220033395-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | ALDH1A1 700/4885KDM4E 4502/4885TSHR 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.